XLO Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
18.7M
+47.8%
12.6M
-7.6%
13.7M
-28.2%
19.1M
+135.8%
8.1M
Cost of Revenue
0
0
0
0
0
Gross Profit
18.7M
+47.8%
12.6M
-7.6%
13.7M
-28.2%
19.1M
+135.8%
8.1M
Operating Expenses
22.2M
-17.1%
26.8M
+4.9%
25.5M
+21.6%
21.0M
-6.5%
22.4M
R&D
14.6M
-26.6%
19.8M
+9.4%
18.1M
+26.5%
14.3M
-6.6%
15.3M
SG&A
7.6M
+10.0%
6.9M
-6.4%
7.4M
+10.9%
6.7M
-6.3%
7.1M
Operating Income
-3491000
+75.3%
-14112000
-19.2%
-11836000
-513.6%
-1929000
+86.6%
-14366000
EBITDA
-3160000
+77.0%
-13768000
-19.6%
-11513000
-624.5%
-1589000
+88.6%
-13985000
Net Income
-6373000
+33.1%
-9529000
-192.0%
10.4M
+163.6%
-16287000
-2.8%
-15844000
EPS (Basic)
$-0.33
+43.1%
$-0.58
$-1.54
+33.0%
$-2.30
EPS (Diluted)
$-0.33
+43.1%
$-0.58
$-1.54
+33.0%
$-2.30
Shares (Diluted)
19.4M
+18.7%
16.3M
10.3M
+49.4%
6.9M
Xilio Therapeutics (XLO) — Financials